Theralase Technologies (CVE:TLT) Shares Up 21.1% – What’s Next?

Shares of Theralase Technologies Inc. (CVE:TLT) were up 21.1% during trading on Monday . The stock traded as high as C$0.23 and last traded at C$0.23. Approximately 222,201 shares changed hands during trading, an increase of 98% from the average daily volume of 112,319 shares. The stock had previously closed at C$0.19.

Theralase Technologies Trading Up 100.0 %

The stock has a market capitalization of C$93.31 million, a P/E ratio of -12.00 and a beta of 1.36. The stock’s fifty day moving average price is C$0.18 and its two-hundred day moving average price is C$0.18. The company has a current ratio of 1.21, a quick ratio of 3.40 and a debt-to-equity ratio of 20.58.

Theralase Technologies (CVE:TLT) last posted its quarterly earnings results on Monday, August 12th. The company reported C($0.01) earnings per share for the quarter. The business had revenue of C$0.10 million for the quarter. Equities research analysts forecast that Theralase Technologies Inc. will post -0.05 EPS for the current year.

About Theralase Technologies

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.